These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 36921901)
41. A short history of health technology assessment in Germany. Perleth M; Gibis B; Göhlen B Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():112-9. PubMed ID: 19500440 [TBL] [Abstract][Full Text] [Related]
42. National Institute for Clinical Excellence (NICE). HTA rhyme and reason? Taylor R Int J Technol Assess Health Care; 2002; 18(2):166-70. PubMed ID: 12053416 [TBL] [Abstract][Full Text] [Related]
43. Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors. Chen G; Peirce V; Marsh W Value Health; 2020 Oct; 23(10):1300-1306. PubMed ID: 33032773 [TBL] [Abstract][Full Text] [Related]
44. Reimbursement agency requirements for health related quality-of-life data: a case study. Lloyd A; Wild D; Gallop K; Cowell W Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):527-37. PubMed ID: 19941430 [TBL] [Abstract][Full Text] [Related]
45. Understanding the National Institute for Health and Care Excellence Severity Premium: Exploring Its Implementation and the Implications for Decision Making and Patient Access. Njoroge MW; Walton M; Hodgson R Value Health; 2024 Jun; 27(6):730-736. PubMed ID: 38447743 [TBL] [Abstract][Full Text] [Related]
47. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study. Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843 [TBL] [Abstract][Full Text] [Related]
48. Exploring uncertainty and use of real-world data in the National Institute for Health and Care Excellence single technology appraisals of targeted cancer therapy. Kang J; Cairns J BMC Cancer; 2022 Dec; 22(1):1268. PubMed ID: 36471259 [TBL] [Abstract][Full Text] [Related]
49. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626 [TBL] [Abstract][Full Text] [Related]
50. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation. Guthrie S; Bienkowska-Gibbs T; Manville C; Pollitt A; Kirtley A; Wooding S Health Technol Assess; 2015 Aug; 19(67):1-291. PubMed ID: 26307643 [TBL] [Abstract][Full Text] [Related]
51. Protocol for data extraction: how real-world data have been used in the National Institute for Health and Care Excellence appraisals of cancer therapy. Kang J; Cairns J BMJ Open; 2022 Jan; 12(1):e055985. PubMed ID: 34992121 [TBL] [Abstract][Full Text] [Related]
52. [Current Consideration of Tonsillectomy and Tonsillotomy]. Geißler K; Guntinas-Lichius O Laryngorhinootologie; 2020 Aug; 99(8):568-582. PubMed ID: 32731293 [TBL] [Abstract][Full Text] [Related]
53. Does the use of health technology assessment have an impact on the utilisation of health care resources? Evidence from two European countries. Corbacho B; Drummond M; Santos R; Jones E; Borràs JM; Mestre-Ferrandiz J; Espín J; Henry N; Prat A Eur J Health Econ; 2020 Jun; 21(4):621-634. PubMed ID: 32026155 [TBL] [Abstract][Full Text] [Related]
54. Review of Relative effectiveness assessments (REAs) of pharmaceuticals at the European network for health technology assessment (EUnetHTA): A first step towards a consolidated European perspective on comparative effectiveness & safety? Chassagnol F; Marcelli G; Wagle J; Giuliani G; Traub D; Schaub V; Ruof J Health Policy; 2020 Sep; 124(9):943-951. PubMed ID: 32622542 [TBL] [Abstract][Full Text] [Related]
55. [Promotion of general health and scientific literacy via consumer and patient information: the role of the IQWiG]. Bastian H; Kaiser T; Matschewsky S Z Arztl Fortbild Qualitatssich; 2005; 99(6):379-85. PubMed ID: 16121654 [TBL] [Abstract][Full Text] [Related]
56. The use of UK primary care databases in health technology assessments carried out by the National Institute for health and care excellence (NICE). Leahy TP; Ramagopalan S; Sammon C BMC Health Serv Res; 2020 Jul; 20(1):675. PubMed ID: 32698805 [TBL] [Abstract][Full Text] [Related]
57. Health technology assessment in England and Wales. Stevens A; Milne R Int J Technol Assess Health Care; 2004; 20(1):11-24. PubMed ID: 15176173 [TBL] [Abstract][Full Text] [Related]
58. Justifying the source of external comparators in single-arm oncology health technology submissions: a review of NICE and PBAC assessments. Appiah K; Rizzo M; Sarri G; Hernandez L J Comp Eff Res; 2024 Feb; 13(2):e230140. PubMed ID: 38174576 [No Abstract] [Full Text] [Related]
59. Inclusion of Carer Health-Related Quality of Life in National Institute for Health and Care Excellence Appraisals. Pennington BM Value Health; 2020 Oct; 23(10):1349-1357. PubMed ID: 33032779 [TBL] [Abstract][Full Text] [Related]
60. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease. Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]